Français Japonais Chinois Allemand Néerlandais Espagnol Portugais

    News

    Medical excellence in Hauts-de-France—the Facing Faces Institute

    The Facing Faces Institute (IFF) was founded in 2009 by Dr. Bernard Devauchelle, head of maxillofacial surgery at Amiens University Hospital Center and known for performing the world's first partial face...

    Health start-up Japet offers relief from back pain

    Antoine Noël and Damien Bratic—both graduates of the Centrale Lille school of engineering—founded Japet Medical Devices to develop a revolutionary new solution for back pain.

    All news

    Health: Lille University, BioVersys and GSK join forces to fight tuberculosis

    03 Feb 2015 | Health Nutrition

    Lille University, BioVersys and GlaxoSmithKline reach first milestone in joint battle against tuberculosis

    Healthcare - Northern France

    In May 2014, Lille University and Swiss biopharmaceutical specialist BioVersys launched a partnership with British pharmaceutical group GlaxoSmithKline to develop a treatment for tuberculosis (TB), and in December 2014 the French and Swiss teams announced that they were moving into the second stage of the project—developing a preclinical drug candidate.

    Their effort is built on over 15 years of work by researchers in Lille, allowing scientists to identify powerful compounds that inactivate drug resistance by sensitizing TB bacteria to established therapies.

    The effort is funded by Wellcome Trust, a global charitable foundation dedicated to improving health, and the partners are using TRIC software, developed by BioVersys to speed the discovery of compounds that inhibit the transcriptional regulators associated with antibiotic resistance.

    “We’re looking forward to developing a powerful tuberculosis treatment, working with GSK’s scientists and our colleagues at Lille University in the months ahead,” said Marc Gitzinger, PhD, BioVersys co-founder and CEO.

    “This project shows how a close partnership between academic teams and pharmaceutical labs can generate an innovative, effective response to critical but neglected medical needs like tuberculosis treatments,” said Professor Xavier Vandendriessche, President of Lille 2 University of Health and Law.

    Tuberculosis is the world’s leading cause of death from bacterial infectious disease.


    Source: http://www.venturekick.ch/BioVersys-achieves-first-milestone-in-project-to-fight-tuberculosis

    Back to news